CYTOKINETICS INC
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
(In thousands, except share data) (Unaudited)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Deficit | |
| Balance, December 31, 2024 | 118,209,139 | $118 | $2,563,876 | $2,398 | $(2,701,764) | $(135,372) |
| Exercise of stock options | 351,985 | — | 7,651 | — | — | 7,651 |
| Vesting of restricted stock units, net of taxes withheld | 659,179 | 1 | (13) | — | — | (12) |
| Stock-based compensation | — | — | 23,549 | — | — | 23,549 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (541) | — | (541) |
| Foreign currency translation adjustments | — | — | — | (312) | — | (312) |
| Net loss | — | — | — | — | (161,376) | (161,376) |
| Balance, March 31, 2025 | 119,220,303 | $119 | $2,595,063 | $1,545 | $(2,863,140) | $(266,413) |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Deficit | |
| Balance, December 31, 2023 | 101,637,922 | $102 | $1,725,823 | $(10) | $(2,112,238) | $(386,323) |
| Exercise of stock options | 1,466,359 | 2 | 29,530 | — | — | 29,532 |
| Vesting of restricted stock units | 695,140 | — | — | — | — | — |
| Shares withheld related to net share settlement of equity awards | (274,256) | — | (18,449) | — | — | (18,449) |
| Issuance of common stock under at-the-market offering, net of issuance costs | 1,237,460 | 1 | 93,639 | — | — | 93,640 |
| Exercise of warrants, net | 11,335 | — | — | — | — | — |
| Stock-based compensation | — | — | 21,612 | — | — | 21,612 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (556) | — | (556) |
| Foreign currency translation adjustments | — | — | — | 27 | — | 27 |
| Net loss | — | — | — | — | (135,643) | (135,643) |
| Balance, March 31, 2024 | 104,773,960 | $105 | $1,852,155 | $(539) | $(2,247,881) | $(396,160) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.